logo
'On borrowed time': State presents schedule for closing Hiram W. Davis Medical Center

'On borrowed time': State presents schedule for closing Hiram W. Davis Medical Center

Yahoo24-05-2025

The timeline for closing the Hiram W. Davis Medical Center by 2027 in Dinwiddie County has been made public, and its plans call for eventual moves of patients to either public or private facilities and an employee-relocation process the state hopes will limit layoffs.
A final process for shuttering the 50-year-old 150-bed facility on the campus of Central State Hospital still must be approved by the General Assembly and governor next winter. A meeting May 21 of the state Joint Commission on Health Care (JCHC) provided the first opportunity for review of that timetable.
There are currently 33 patients at the hospital, with three of them likely to be discharged by July. Of those remaining, half are expected to go to either the Southeast Virginia Training Center in Chesapeake, or into an intermediate-care facility or group home.
As for the 152 staff members at the medical center, some of them will transfer to the new Central State Hospital currently under construction along with some of the medical-center services. Others will be offered positions at other DBHDS facilities or retire.
Closure of Davis Medical Center became the only option after DBHDS determined that it costs more to renovate the old building rather than close it.
Its shortfalls became apparent when the building began having problems with its water system due to aging pipes. The center's design and construction did not allow for expansion or invasive renovations that would cause patient and staff relocations.
'It really is on borrowed time,' DBHDS Commissioner Dr. Nelson Smith told the JCHC. Temporary heating and air-conditioning units have been set up in the hospital's hallways, and at one point, staffers had to use bowls of water to bathe patients due to levels of legionella in the system.
'Thankfully, that has been mitigated,' Smith told the commission members, 'but that doesn't mean we're not at risk or out of the woods in the future.'
Simply put, Smith said, DBHDS patients deserve the highest quality of medical care, 'and this facility doesn't represent them.'
Another driving force for the center's closure, Smith said, is the trend toward private-sector healthcare taking over many of the services once only offered by the state. Those services allow patients to be treated closer to home than in one centralized facility.Smith said DBHDS is spending $1.5 million to upgrade the Southeastern Virginia Training Center in Chesapeake to accommodate up to 15 of the existing Davis patients. Most of the patients eligible for transfer to Chesapeake are likely to move into care settings closer to their homes, but DBHDS expects at least five of them to opt for SEVTC.
Smith estimated that two residences at SEVTC would have to be fixed up to accommodate the Davis transfers.
The term 'training center' is a misnomer, Smith said, because the center actually is made up of 15 five-bed living quarters, all under skilled care.
'It's more like a neighborhood,' Smith said.
At one point, Virginia had five training centers, including one adjacent to Central State Hospital in Dinwiddie. All but Chesapeake were forced to close as part of a federal investigation into care at these centers.
In the interim, Smith said, more opportunities for mental-health care in the private sector meant less of a reliance on the state for services.
Plans call for the final version of the timeline to be officially submitted to the governor and the General Assembly money committees by Nov. 1 in time for consideration in the 2026 legislative session.
Bill Atkinson (he/him/his) is an award-winning journalist who covers breaking news, government and politics. Reach him at batkinson@progress-index.com or on X (formerly known as Twitter) at @BAtkinson_PI.
This article originally appeared on The Progress-Index: State gives timeline for closing Hiram W. Davis Medical Center

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASCO 2025: Key Updates in Early Breast Cancer Care
ASCO 2025: Key Updates in Early Breast Cancer Care

Medscape

time18 minutes ago

  • Medscape

ASCO 2025: Key Updates in Early Breast Cancer Care

Mariana Chavez MacGregor, MD, MSc, comments on how the ASCO 2025 meeting delivered a wealth of impactful data, particularly in the early-stage breast cancer setting. Trials like neoCARHP and CompassHER2 raised important questions about de-escalating therapy for HER2-positive patients, challenging the role of carboplatin and demonstrating strong pathologic complete response rates with shorter regimens. Long-term data from SOFT and TEXT reinforced the survival benefits of ovarian suppression plus an aromatase inhibitor in high-risk premenopausal patients, and the OASIS 4 study showed promise with elinzanetant in managing vasomotor symptoms. Across subtypes, including triple-negative disease, and with the growing role of AI and circulating tumor DNA, the meeting emphasized more personalized, less toxic approaches to care.

ASCO 2025: Key Highlights in Advanced Lung Cancer
ASCO 2025: Key Highlights in Advanced Lung Cancer

Medscape

time18 minutes ago

  • Medscape

ASCO 2025: Key Highlights in Advanced Lung Cancer

Just returned from ASCO 2025, Isabel Preeshagul, DO, comments on intriguing data that were presented, including results from REZILIENT1, which showed a 35% response rate for zipalertinib in patients with epidermal growth factor receptor exon 20-altered stage IV non-small cell lung cancer (NSCLC), even those previously treated with targeted therapies, with manageable toxicity. An unexpected finding from another study in the advanced NSCLC space suggested that administering immunochemotherapy before 3:00 PM was associated with better outcomes, possibly due to circadian influences on immune response. In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and exertional shortness of breath. Finally, Dr Preeshagul notes how the IMforte study reported promising results for maintenance atezolizumab plus lurbinectedin, with improved progression-free survival and overall survival, making it a potential option pending further risk-benefit discussion.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store